By Dean Seal
Shares of Akoya Biosciences tumbled after the company cut its full-year revenue outlook and said it was considering strategic alternatives.
The stock was down 21% at $2.46 in premarket trading. Shares had already fallen 36% year-to-date when the market closed Thursday.
The maker of platforms for spatial phenotyping said after yesterday's bell that it now expects $80 million to $85 million in revenue this year, rather than $96 million to $104 million as previously forecast.
The company said the revision was driven by "persistent macro challenges" during the year and that it is actively looking at a range of strategic alternatives.
In its third quarter, revenue fell 25% to $18.8 million. Analysts polled by FactSet had been expecting a slight uptick in revenue to $25.3 million.
The shortfall was largely due to ongoing constraints in spending on capital equipment in the market for life science tools, Chief Executive Brian McKelligon said.
The company's quarterly loss narrowed to $10.5 million, or 21 cents a share, compared with $12.9 million, or 26 cents a share, a year ago.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 15, 2024 08:22 ET (13:22 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。